Centessa Pharmaceuticals - CNTA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.75
  • Forecasted Upside: 54.57%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.72
▼ -0.03 (-0.80%)

This chart shows the closing price for CNTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Centessa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTA

Analyst Price Target is $5.75
▲ +54.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Centessa Pharmaceuticals in the last 3 months. The average price target is $5.75, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 54.57% upside from the last price of $3.72.

This chart shows the closing price for CNTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Centessa Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyLower TargetUnderweight$5.00 ➝ $4.00Low
8/12/2022Morgan StanleyDowngradeOverweight ➝ Underweight$10.00 ➝ $5.00Low
8/11/2022BMO Capital MarketsLower Target$19.00 ➝ $11.00Low
8/11/2022The Goldman Sachs GroupLower TargetNeutral$5.00 ➝ $4.00Low
7/15/2022Morgan StanleyLower TargetOverweight$15.00 ➝ $10.00Low
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$19.00High
6/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$4.00High
5/24/2022The Goldman Sachs GroupLower TargetNeutral$12.00 ➝ $8.00Low
5/24/2022Morgan StanleyLower TargetOverweight$19.00 ➝ $15.00Low
4/5/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00Medium
2/11/2022The Goldman Sachs GroupInitiated CoverageNeutral$12.00High
6/22/2021Jefferies Financial GroupInitiated CoverageBuy$35.00High
6/22/2021Morgan StanleyInitiated CoverageOverweight$37.00High
6/22/2021The Goldman Sachs GroupInitiated CoverageBuy$42.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/10/2022
  • 4 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/9/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Centessa Pharmaceuticals logo
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Read More

Today's Range

Now: $3.72
Low: $3.60
High: $3.75

50 Day Range

MA: $3.60
Low: $3.05
High: $4.01

52 Week Range

Now: $3.72
Low: $2.88
High: $11.19

Volume

30,536 shs

Average Volume

167,933 shs

Market Capitalization

$351.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Centessa Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Centessa Pharmaceuticals in the last twelve months: BMO Capital Markets, Jefferies Financial Group Inc., Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for CNTA.

What is the current price target for Centessa Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Centessa Pharmaceuticals in the last year. Their average twelve-month price target is $5.75, suggesting a possible upside of 54.6%. BMO Capital Markets has the highest price target set, predicting CNTA will reach $11.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $4.00 for Centessa Pharmaceuticals in the next year.
View the latest price targets for CNTA.

What is the current consensus analyst rating for Centessa Pharmaceuticals?

Centessa Pharmaceuticals currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CNTA, but not buy more shares or sell existing shares.
View the latest ratings for CNTA.

What other companies compete with Centessa Pharmaceuticals?

How do I contact Centessa Pharmaceuticals' investor relations team?

Centessa Pharmaceuticals' physical mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The company's listed phone number is 44-73-9178-9784 and its investor relations email address is [email protected] The official website for Centessa Pharmaceuticals is www.centessa.com. Learn More about contacing Centessa Pharmaceuticals investor relations.